Abstract: An array substrate and a manufacturing method therefor, and a display apparatus are provided. The array substrate includes an underlay substrate, and at least one first transistor, at least one data line and at least one pixel electrode disposed on the underlay substrate. The at least one first transistor includes a first active layer and a first gate; the first gate is located on a side of the first active layer away from the underlay substrate, and orthographic projections of the first gate and the first active layer on the underlay substrate are at least partially overlapped. The first active layer is electrically connected to the data line and the pixel electrode, respectively. The data line is located on a side of the first active layer close to the underlay substrate, and the pixel electrode is located on a side of the first gate away from the underlay substrate.

Abstract: Provided are an array substrate and a method for manufacturing the array substrate, a display panel and a display device, belonging to the field of display technologies. The array substrate includes a base substrate and a driving thin-film transistor disposed on the base substrate. The driving thin-film transistor includes a first gate, a first insulating layer, a first active layer, a second insulating layer, and a first source/drain electrode which are sequentially laminated on the base substrate. The thickness of the first insulating layer is greater than the thickness of the second insulating layer. Therefore, the regulating ability of the first gate of the driving thin-film transistor over the first active layer is reduced, and the subthreshold swing of the driving thin-film transistor is increased, thereby improving the adjusting ability of the driving thin-film transistor over the grayscale of the light-emitting device on the display panel.

Abstract: Disclosed is a prefabricated laminated slab made in accordance with a pretensioning fibermesh anti-cracking process and a manufacturing method thereof, and belongs to the technical field of fabricated structure engineering. The prefabricated laminated slab comprises a concrete layer, fiber grids, distribution bars and truss bars. The fiber grids are subjected to prestress tensioning and pouring to form a novel laminated slab with the pretensioning process, an overall pouring process of layered formworks is adopted, the construction problem during prestress tensioning of the fiber grids of the component can be effectively solved, the crack resistance of the laminated slab can be improved by adopting the prestress grids, the rigidity is increased, and the crack width under normal use conditions is reduced.

Abstract: Chimeric antigen receptors (CARs) including an antigen binding domain specifically binding to coronavirus spike protein, nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Methods of treating a subject with coronavirus, including administering to the subject an immune cell expressing a disclosed CAR are also provided.

Abstract: The technology provides a rich attention mechanism for structured information extraction of web pages and other electronic documents. An input layer of a model obtains system, information associated with the document, including field tokens representing respective fields to be extracted from the document, structured document type tokens associated, and text tokens from a text sequence in the document. An encoder connects the field tokens, the S type tokens and the text tokens according to a set of different attention patterns. The encoder generates an overall token representation based on the set of different attention patterns. An output layer of the model extracts a final text span for the each of the respective fields from the set of text tokens. The extracted final text span for each of the respective fields is stored in memory, and can be produced in response to a search query, analytics evaluation or other request.

Abstract: Chimeric antigen receptors (CARs) including an scFv binding to coronavirus spike protein (S309 scFv), nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and cells expressing the CARs are provided. Methods of treating a subject with coronavirus are also provided, including administering to the subject a modified immune cell expressing a disclosed CAR.

Abstract: Disclosed herein are methods and compositions for generating immunotherapeutic cells (e.g., NK and T cells) with enhanced cytotoxicity and capacity for expansion thereof. The methods and compositions disclosed herein can further be used for enhanced expansion of CAR-modified NK and T cells with increased cytotoxicity.

Abstract: Modified single chain variable fragments (scFv) that specifically bind CD147 are provided. Also provided are chimeric antigen receptors (CARs) including the modified CD147 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs. Methods of treating a subject with cancer including administering to the subject an immune cell expressing a disclosed CD147-CAR are also provided.

Abstract: Chimeric antigen receptors (CARs) including an antigen binding domain specifically binding to coronavirus spike protein, nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Methods of treating a subject with coronavirus, including administering to the subject an immune cell expressing a disclosed CAR are also provided.

Abstract: Embodiments of the disclosure concern methods of determining the effectiveness of immune cells, such as T cells, with particular chimeric antigen receptors. In specific embodiments, a synapse between the CAR and the tumor antigen is measured for structure, signaling, and functionality by imaging. As such, the quality of the synapse is determined and positively correlates with effectiveness of the particular CAR immune cells.

Abstract: Embodiments of the disclosure concern methods of determining the effectiveness of immune cells, such as T cells, with particular chimeric antigen receptors. In specific embodiments, a synapse between the CAR and the tumor antigen is measured for structure, signaling, and functionality by imaging. As such, the quality of the synapse is determined and positively correlates with effectiveness of the particular CAR immune cells.

Abstract: Embodiments of the disclosure concern methods of determining the effectiveness of immune cells, such as T cells, with particular chimeric antigen receptors. In specific embodiments, a synapse between the CAR and the tumor antigen is measured for structure, signaling, and functionality by imaging. As such, the quality of the synapse is determined and positively correlates with effectiveness of the particular CAR immune cells.

Abstract: A vertical cell pairing (VCP) system comprising: a substrate having a top surface; at least one micropit formed in the top surface of the substrate, the at least one micropit being sized to seat a cell; and at least one microtrap positioned adjacent the top surface of the substrate, the at least one microtrap comprising a body having a vertical slot, wherein the vertical slot has an opening and an exit, the vertical slot being sized to pass fluid therethrough but to prevent a cell from passing therethrough; wherein the at least one microtrap is disposed relative to the at least one micropit so that a cell seated in the at least one micropit is in cell-cell communication with a cell disposed at the opening of the vertical slot.

Abstract: Provided is a preparation method of a crystalline silicon film.

Abstract: Provided is a preparation method of a crystalline silicon film. The method includes: 1) forming a mask for making a periodic silicon rod array on a monocrystalline silicon wafer substrate, and forming the periodic silicon rod array on the monocrystalline silicon substrate by a wet chemical etching or dry etching process; 2) forming barrier layers on the surface of the monocrystalline silicon substrate and the surface of the silicon rod array for next selectively epitaxial growth of silicon; 3) exposing silicon cores on the heads of the rod array by a selective etching process to form a silicon seed array; 4) growing a continuous silicon film at the top of the rod array by a chemical vapor deposition method using the exposed silicon cores as seeds for selectively epitaxial growth of silicon; and 5) lifting off the silicon film and transferring the silicon film to a preset substrate, and the seeded substrate is reusable.

Abstract: The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

Abstract: The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

Abstract: The invention relates to methods and products for analyzing or processing a heparin sample. In one embodiment, the methods comprise contacting the sample with heparinase I, heparinase II and heparinase III, determining the amount of a signature component in the sample using a separation method, and making a determination about the sample based upon a comparison of the amount of the signature component in the sample to a reference database for a heparin.

Abstract: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Abstract: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.